Targeting apoptosis proteins in hematological malignancies

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 325-334

  Droin, Nathalie ^a,b   Guéry, Leslie ^b   Benikhlef, Naïma ^b   Solary, Eric ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Apoptosis; Bcl 2; Drugs; Hematological diseases; IAPs; TRAIL

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTHRACYCLINE; BCL2 RELATED PROTEIN A1; CASPASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DULANERMIN; FLUDARABINE; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; LEXATUMUMAB; MAPATUMUMAB; OBATOCLAX; OBLIMERSEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN BCL B; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; RAPAMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CONFORMATIONAL TRANSITION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; INTRACELLULAR SIGNALING; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SOLID TUMOR;

INTRACISTERNAL A-PARTICLES;

EID: 84876092645     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.016     Document Type: Review

References (106)

1. Ribeil J.A., Zermati Y., Vandekerckhove J., Cathelin S., Kersual J., Dussiot M., Coulon S., Moura I.C., Zeuner A., Kirkegaard-Sørensen T., Varet B., Solary E., Garrido C., Hermine O. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 2007, 445:102-105.
2. Jacquel A., Benikhlef N., Paggetti J., Lalaoui N., Guery L., Dufour E.K., Ciudad M., Racoeur C., Micheau O., Delva L., Droin N., Solary E. Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. Blood 2009, 114:3633-3641.
3. De Botton S., Sabri S., Daugas E., Zermati Y., Guidotti J.E., Hermine O., Kroemer G., Vainchenker W., Debili N. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002, 100:1310-1317.
4. Morison I.M., Cramer Bordé E.M., Cheesman E.J., Cheong P.L., Holyoake A.J., Fichelson S., Weeks R.J., Lo A., Davies S.M., Wilbanks S.M., Fagerlund R.D., Ludgate M.W., da Silva Tatley F.M., Coker M.S., Bockett N.A., Hughes G., Pippig D.A., Smith M.P., Capron C., Ledgerwood E.C. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat. Genet. 2008, 40:387-389.
5. Weber G.F., Menko A.S. The canonical intrinsic mitochondrial death pathway has a non-apoptotic role in signaling lens cell differentiation. J. Biol. Chem. 2005, 280:22135-22145.
6. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat. Immunol. 2010, 11:21-27.
7. Fox S., Leitch A.E., Duffin R., Haslett C., Rossi A.G. Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease. J. Innate Immun. 2010, 2:216-227.
8. Claessens Y.E., Park S., Dubart-Kupperschmitt A., Mariot V., Garrido C., Chrétien S., Dreyfus F., Lacombe C., Mayeux P., Fontenay M. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 2005, 105:4035-4042.
9. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., Kiladjian J.J., Ribrag V., Fenaux P., Kroemer G. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
10. Traver D., Akashi K., Weissman I.L., Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998, 9:47-57.
11. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102:13944-13949.
12. Varfolomeev E., Wayson S.M., Dixit V.M., Fairbrother W.J., Vucic D. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 and TRAF2. J. Biol. Chem. 2006, 281:29022-29029.
13. Schlette E.J., Medeiros L.J., Goy A., Lai R., Rassidakis G.Z. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J. Clin. Oncol. 2004, 22:1682-1688.
14. Mérino D., Lalaoui N., Morizot A., Solary E., Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin. Ther. Targets 2007, 11:1299-1314.
15. Schmitt C.A., Rosenthal C.T., Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 2000, 6:1029-1035.
16. Rubio-Moscardo F., Blesa D., Mestre C., Siebert R., Balasas T., Benito A., Rosenwald A., Climent J., Martinez J.I., Schilhabel M., Karran E.L., Gesk S., Esteller M., deLeeuw R., Staudt L.M., Fernandez-Luna J.L., Pinkel D., Dyer M.J., Martinez-Climent J.A. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005, 106:3214-3222.
17. Sprick M.R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M.A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but cannot functionally substitute caspase-8. EMBO J. 2002, 21:4520-4530.
18. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 22:5579-5588.
19. Mérino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 2006, 26:7046-7055.
20. Nesterov A., Nikrad M., Johnson T., Kraft A.S. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2004, 64:3922-3927.
21. Nieminen A.I., Partanen J.I., Hau A., Klefstrom J. C-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J. 2007, 26:1055-1067.
22. Pennarun B., Meijer A., de Vries E.G., Kleibeuker J.H., Kruyt F., de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim. Biophys. Acta. 2010, 1805:123-140.
23. Soria J.C., Smit E., Khayat D., Besse B., Yang X., Hsu C.P., Reese D., Wiezorek J., Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1527-1533.
24. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., Novotny W., Goldwasser M.A., Tohnya T.M., Lum B.L., Ashkenazi A., Jubb A.M., Mendelson D.S. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28:2839-2846.
25. Younes A., Vose J.M., Zelenetz A.D., Smith M.R., Burris H.A., Ansell S.M., Klein J., Halpern W., Miceli R., Kumm E., Fox N.L., Czuczman M.S. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer. 2010, 103:1783-1787.
26. Wakelee H.A., Patnaik A., Sikic B.I., Mita M., Fox N.L., Miceli R., Ullrich S.J., Fisher G.A., Tolcher A.W. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol. 2010, 21:376-381.
27. Mullican S.E., Zhang S., Konopleva M., Ruvolo V., Andreeff M., Milbrandt J., Conneely O.M. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat. Med. 2007, 13:730-735.
28. Kim S.H., Ricci M.S., El-Deiry W.S. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 2008, 68:2062-2064.
29. Rosato R.R., Almenara J.A., Coe S., Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007, 67:9490-9500.
30. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N.T., Kumar S.K., Smith B.D., Karp J.E., Adjei A.A., Kaufmann S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 2007, 282:29831-29846.
31. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
32. Loeder S., Zenz T., Schnaiter A., Mertens D., Winkler D., Döhner H., Debatin K.M., Stilgenbauer S., Fulda S. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 2009, 69:8977-8986.
33. Daniel D., Yang B., Lawrence D.A., Totpal K., Balter I., Lee W.P., Gogineni A., Cole M.J., Yee S.F., Ross S., Ashkenazi A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007, 110:4037-4046.
34. Maddipatla S., Hernandez-Ilizaliturri F.J., Knight J., Czuczman M.S. Augmented antitumor activity against B cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin. Cancer Res. 2007, 13:4556-4564.
35. Sayers T.J., Brooks A.D., Koh C.Y., Ma W., Seki N., Raziuddin A., Blazar B.R., Zhang X., Elliott P.J., Murphy W.J. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102:303-310.
36. Liu Q., Hilsenbeck S., Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003, 101:4078-4087.
37. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64:337-346.
38. Morales J.C., Ruiz-Magaña M.J., Carranza D., Ortiz-Ferrón G., Ruiz-Ruiz C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett. 2010, 297:91-100.
39. Fiskus W., Rao R., Fernandez P., Herger B., Yang Y., Chen J., Kolhe R., Mandawat A., Wang Y., Joshi R., Eaton K., Lee P., Atadja P., Peiper S., Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008, 112:2896-2905.
40. Seal S., Hockenbery D.M., Spaulding E.Y., Kiem H.P., Abbassi N., Deeg H.J. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. Exp. Hematol. 2008, 36:1660-1672.
41. MacFarlane M., Harper N., Snowden R.T., Dyer M.J., Barnett G.A., Pringle J.H., Cohen G.M. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002, 21:6809-6818.
42. Lozupone F., Lugini L., Matarrese P., Luciani F., Federici C., Iessi E., Margutti P., Stassi G., Malorni W., Fais S. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem. 2004, 279:9199-9207.
43. Kuo W.C., Yang K.T., Hsieh S.L., Lai M.Z. Ezrin is a negative regulator of death receptor-induced apoptosis. Oncogene 2010, 29:1374-1383.
44. Menoret E., Gomez-Bougie P., Geffroy-Luseau A., Daniels S., Moreau P., Le Gouill S., Harousseau J.L., Bataille R., Amiot M., Pellat-Deceunynck C. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006, 108:1346-1352.
45. O'Brien S., Moore J.O., Boyd T.E., Larratt L.M., Skotnicki A.B., Koziner B., Chanan-Khan A.A., Seymour J.F., Gribben J., Itri L.M., Rai K.R. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 2009, 27:5208-5212.
46. Grünweller A., Hartmann R.K. Locked nucleic acid oligonucleotides: the next generation of antisense agents?. Biodrugs 2007, 21:235-243.
47. Dürig J., Dührsen U., Klein-Hitpass L., Worm J., Hansen J.B., Orum H., Wissenbach M. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 2011, 25(4):638-647.
48. Kuo C.C., Liang C.M., Lai C.Y., Liang S.M. Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J. Immunol. 2007, 178:6100-6108.
49. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 2008, 7(12):989-1000.
50. Shoemaker A.R., Oleksijew A., Bauch J., Belli B.A., Borre T., Bruncko M., Deckwirth T., Frost D.J., Jarvis K., Joseph M.K., Marsh K., McClellan W., Nellans H., Ng S., Nimmer P., O'Connor J.M., Oltersdorf T., Qing W., Shen W., Stavropoulos J., Tahir S.K., Wang B., Warner R., Zhang H., Fesik S.W., Rosenberg S.H., Elmore S.W. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006, 66:8731-8739.
51. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
52. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006, 10:389-399.
53. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
54. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., Kelly P.N., Ekert P.G., Metcalf D., Roberts A.W., Huang D.C., Kile B.T. Programmed a nuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
55. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
56. Kang M.H., Wan Z., Kang Y.H., Sposto R., Reynolds C.P. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J. Natl. Cancer Inst. 2008, 100:580-595.
57. High L.M., Szymanska B., Wilczynska-Kalak U., Barber N., O'Brien R., Khaw S.L., Vikstrom I.B., Roberts A.W., Lock R.B. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol. Pharmacol. 2010, 77:483-494.
58. Chen S., Dai Y., Pei X.Y., Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol. Cell Biol. 2009, 29:6149-6169.
59. Whitecross K.F., Alsop A.E., Cluse L.A., Wiegmans A., Banks K.M., Coomans C., Peart M.J., Newbold A., Lindemann R.K., Johnstone R.W. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009, 113:1982-1991.
60. Wiegmans A.P., Alsop A., Bots M., Cluse L.A., Williams S.P., Banks K.M., Ralli R., Scott C.L., Frenzel A., Villunger A., Johnstone R.W. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res. 2011, 71:3603-3615.
61. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., Kimura S., Ottmann O.G., Druker B.J., Villunger A., Roberts A.W., Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. USA 2006, 103(40):14907-14912.
62. Kuroda J., Kimura S., Andreeff M., Ashihara E., Kamitsuji Y., Yokota A., Kawata E., Takeuchi M., Tanaka R., Murotani Y., Matsumoto Y., Tanaka H., Strasser A., Taniwaki M., Maekawa T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br. J. Haematol. 2008, 140(2):181-190.
63. Li G., Miskimen K.L., Wang Z., Xie X.Y., Tse W., Gouilleux F., Moriggl R., Bunting K.D. Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 2010, 24(8):1397-1405.
64. Paoluzzi L., Gonen M., Bhagat G., Furman R.R., Gardner J.R., Scotto L., Gueorguiev V.D., Heaney M.L., Manova K., O'Connor O.A. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008, 112:2906-2916.
65. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., Kaluarachchi K., Bornmann W., Duvvuri S., Taegtmeyer H., Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 2010, 120:142-156.
66. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., Goulet D., Viallet J., Bélec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R.W., Beauparlant P., Shore G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 2007, 104:19512-19517.
67. Pérez-Galán P., Roué G., Villamor N., Campo E., Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-4449.
68. Schimmer A.D., O'Brien S., Kantarjian H., Brandwein J., Cheson B.D., Minden M.D., Yee K., Ravandi F., Giles F., Schuh A., Gupta V., Andreeff M., Koller C., Chang H., Kamel-Reid S., Berger M., Viallet J., Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:8295-8301.
69. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., Bornmann W., Kantarjian H., Viallet J., Samudio I., Andreeff M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008, 68(9):3413-3420.
70. Bonapace L., Bornhauser B.C., Schmitz M., Cario G., Ziegler U., Niggli F.K., Schäfer B.W., Schrappe M., Stanulla M., Bourquin J.P. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 2010, 120:1310-1323.
71. Balakrishnan K., Wierda W.G., Keating M.J., Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008, 112:1971-1980.
72. Wei J., Kitada S., Rega M.F., Emdadi A., Yuan H., Cellitti J., Stebbins J.L., Zhai D., Sun J., Yang L., Dahl R., Zhang Z., Wu B., Wang S., Reed T.A., Wang H.G., Lawrence N., Sebti S., Reed J.C., Pellecchia M. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol. Cancer Ther. 2009, 8:904-913.
73. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., Dawson M.I., Reed J.C., Zhang X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116:527-540.
74. Kolluri S.K., Zhu X., Zhou X., Lin B., Chen Y., Sun K., Tian X., Town J., Cao X., Lin F., Zhai D., Kitada S., Luciano F., O'Donnell E., Cao Y., He F., Lin J., Reed J.C., Satterthwait A.C., Zhang X.K. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008, 14:285-298.
75. Luciano F., Krajewska M., Ortiz-Rubio P., Krajewski S., Zhai D., Faustin B., Bruey J.M., Bailly-Maitre B., Lichtenstein A., Kolluri S.K., Satterthwait A.C., Zhang X.K., Reed J.C. Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma. Blood 2007, 109:3849-3855.
76. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009, 23:467-476.
77. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288:874-877.
78. Bratton S.B., Lewis J., Butterworth M., Duckett C.S., Cohen G.M. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95- and Bax-induced apoptosis. Cell Death Differ. 2002, 9:881-892.
79. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., Brink R., Leverkus M., Tergaonkar V., Schneider P., Callus B.A., Koentgen F., Vaux D.L., Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
80. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 2001, 8(3):613-621.
81. Martins L.M., Iaccarino I., Tenev T., Gschmeissner S., Totty N.F., Lemoine N.R., Savopoulos J., Gray C.W., Creasy C.L., Dingwall C., Downward J. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J. Biol. Chem. 2002, 277(1):439-444.
82. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., Tamai K., Craig C.G., McBurney M.W., Korneluk R.G. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat. Cell Biol. 2001, 2:128-133.
83. Wäldele K., Silbermann K., Schneider G., Ruckes T., Cullen B.R., Grassmann R. Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood 2006, 107:4491-4499.
84. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., Scudiero D.A., Tudor G., Qui Y.H., Monks A., Andreeff M., Reed J.C. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukaemia's. Clin. Cancer Res. 2000, 6:1796-1803.
85. LaCasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
86. Dineen S.P., Roland C.L., Greer R., Carbon J.G., Toombs J.E., Gupta P., Bardeesy N., Sun H., Williams N., Minna J.D., Brekken R.A. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 2010, 70:2852-2861.
87. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
88. Cheung H.H., Mahoney D.J., Lacasse E.C., Korneluk R.G. Down-regulation of c-FLIP enhances death of cancer cells by smac mimetic compound. Cancer Res. 2009, 69:7729-7738.
89. Petersen S.L., Peyton M., Minna J.D., Wang X. Overcoming cancer cell resistance to smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc. Natl. Acad. Sci. USA 2010, 107:11936-11941.
90. Dean E., Jodrell D., Connolly K., Danson S., Jolivet J., Durkin J., Morris S., Jowle D., Ward T., Cummings J., Dickinson G., Aarons L., Lacasse E., Robson L., Dive C., Ranson M. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J. Clin. Oncol. 2009, 27:1660-1666.
91. Schimmer A.D., Estey E.H., Borthakur G., Carter B.Z., Schiller G.J., Tallman M.S., Altman J.K., Karp J.E., Kassis J., Hedley D.W., Brandwein J., Xu W., Mak D.H., LaCasse E., Jacob C., Morris S.J., Jolivet J., Andreeff M. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J. Clin. Oncol. 2009, 27:4741-4746.
92. Carter B.Z., Gronda M., Wang Z., Welsh K., Pinilla C., Andreeff M., Schober W.D., Nefzi A., Pond G.R., Mawji I.A., Houghten R.A., Ostresh J., Brandwein J., Minden M.D., Schuh A.C., Wells R.A., Messner H., Chun K., Reed J.C., Schimmer A.D. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005, 105:4043-4050.
93. Carter B.Z., Mak D.H., Morris S.J., Borthakur G., Estey E., Byrd A.L., Konopleva M., Kantarjian H., Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38-cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011, 16:67-74.
94. Talbot D.C., Ranson M., Davies J., Lahn M., Callies S., André V., Kadam S., Burgess M., Slapak C., Olsen A.L., McHugh P.J., de Bono J.S., Matthews J., Saleem A., Price P. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res. 2010, 16:6150-6158.
95. Hansen J.B., Fisker N., Westergaard M., Kjaerulff L.S., Hansen H.F., Thrue C.A., Rosenbohm C., Wissenbach M., Orum H., Koch T. SPC3042: a proapoptotic survivin inhibitor. Mol. Cancer Ther. 2008, 7:2736-2745.
96. Sapra P., Wang M., Bandaru R., Zhao H., Greenberger L.M., Horak I.D. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleos. Nucleot. Nucl. Acids 2010, 29:97-112.
97. Nikolovska-Coleska Z., Xu L., Hu Z., Tomita Y., Li P., Roller P.P., Wang R., Fang X., Guo R., Zhang M., Lippman M.E., Yang D., Wang S. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 2004, 47:2430-2440.
98. Chen J., Nikolovska-Coleska Z., Wang G., Qiu S., Wang S. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg. Med. Chem. Lett. 2006, 16:5805-5808.
99. Ahn K.S., Sethi G., Aggarwal B.B. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol. Pharmacol. 2007, 71:209-219.
100. Tolcher A.W., Mita A., Lewis L.D., Garrett C.R., Till E., Daud A.I., Patnaik A., Papadopoulos K., Takimoto C., Bartels P., Keating A., Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 2008, 26:5198-5203.
101. Gyurkocza B., Plescia J., Raskett C.M., Garlick D.S., Lowry P.A., Carter B.Z., Andreeff M., Meli M., Colombo G., Altieri D.C. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Instrum. 2006, 98:1068-1077.
102. Ciesielski M.J., Ahluwalia M.S., Munich S.A., Orton M., Barone T., Chanan-Khan A., Fenstermaker R.A. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol. Immun. 2010, 59:1211-1221.
103. Gyan E., Frisan E., Beyne-Rauzy O., Deschemin J.C., Pierre-Eugene C., Randriamampita C., Dubart-Kupperschmitt A., Garrido C., Dreyfus F., Mayeux P., Lacombe C., Solary E., Fontenay M. Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia 2008, 22:1864-1873.
104. Sancho-Martinez I., Martin.-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle. 2009, 8:838-842.
105. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11:77-84.
106. Inoue S., Mai A., Dyer M.J. Cohen GM Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006, 66:6785-6792.